# Plasma rich in growth factors in alveolar ridge preservation: randomized, controlled clinical trial

**Authors:** Eduardo Anitua, Alia Murias-Freijo, Joseba Loroño, Markel Loroño, Antonio González-Mosquera, Lucia Anitua, Mohammad H. Alkhraisat

PMC · DOI: 10.1007/s00784-026-06769-z · 2026-03-23

## TL;DR

This study shows that plasma rich in growth factors improves healing and bone regeneration after tooth extraction in the aesthetic zone.

## Contribution

The novel contribution is demonstrating PRGF's efficacy in alveolar ridge preservation through a randomized clinical trial.

## Key findings

- PRGF significantly reduced postoperative pain and improved soft tissue healing.
- PRGF enhanced new bone formation and preserved the alveolar ridge dimensions.
- No significant differences in inflammation were observed between PRGF and control groups.

## Abstract

The objective of this study is to evaluate the efficacy of Plasma rich in growth factors (PRGF) compared to spontaneous healing in alveolar ridge preservation of the aesthetic zone.

This randomized and controlled clinical trial included 46 patients requiring simple-tooth extraction in the aesthetic zone and subsequent implant placement. The extraction sockets were treated either with PRGF or allowed to heal spontaneously. Postoperative healing was assessed by pain, Landry's soft tissue healing index, and inflammation index at 3, 7, and 15 days after tooth extraction. Histomorphometric bone regeneration was evaluated in biopsies harvested after 12 weeks of healing. Dimensional alveolar ridge measurements were performed at baseline and 12 weeks. Any postoperative complications and adverse effects were registered. Statistical analysis was performed to assess the differences between the study groups.

PRGF significantly enhanced postoperative healing, as evidenced by statistically significant reductions in pain on day 3 (p = 0.036) and improved soft tissue healing on days 3 (p = 0.047), 5 (p = 0.012), and 7 (p = 0.027). No significant differences were observed between groups regarding postoperative inflammation. The new bone formation was significantly improved with PRGF treatment (p = 0.024), with a median of 36.1% (range: 15.8% to 58.9%) in the control group compared to 48.7% (range: 31.9% to 92.3%) in the PRGF group. PRGF contributed to improved dimensional stability of the alveolar ridge at 12 weeks.

PRGF improved healing following tooth extraction by promoting soft tissue healing and reducing postoperative pain. Additionally, it enhanced bone regeneration and contributed to better preservation of the alveolar ridge.

The online version contains supplementary material available at 10.1007/s00784-026-06769-z.

## Full-text entities

- **Genes:** COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, SP7 (Sp7 transcription factor) [NCBI Gene 121340] {aka OI11, OI12, OSX, osterix}, AOC1 (amine oxidase copper containing 1) [NCBI Gene 26] {aka ABP, ABP1, DAO, DAO1, KAO, KDAO}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}
- **Diseases:** horizontal bone deficiency (MESH:D009759), autoimmune disease (MESH:D001327), alveolar osteitis (MESH:D004368), coagulopathy (MESH:D001778), chronic hepatitis (MESH:D006521), angiomas (MESH:D006391), malignant tumors (MESH:D009369), tooth extraction (MESH:D014076), dehiscence (MESH:D013529), halitosis (MESH:D006209), Inflammation (MESH:D007249), ischemic heart disease (MESH:D017202), COVID-19 (MESH:D000086382), liver cirrhosis (MESH:D008103), swelling (MESH:D004487), injuries (MESH:D014947), bleeding (MESH:D006470), infection (MESH:D007239), Postoperative (MESH:D019106), bone defect (MESH:D001847), carious lesions (MESH:D003731), ARP (MESH:C537758), periodontal disease (MESH:D010510), negative (MESH:D064726), metabolic bone disease (MESH:D001851), Postoperative pain (MESH:D010149), Pain (MESH:D010146), tooth fracture (MESH:D014082), Poorly controlled diabetes mellitus (MESH:D003920)
- **Chemicals:** paraffin (MESH:D010232), formalin (MESH:D005557), articaine hydrochloride (MESH:D002355), Metamizole (MESH:D004177), alginate (MESH:D000464), ARP (-), Paracetamol (MESH:D000082), bisphosphonates (MESH:D004164), Alcohol (MESH:D000438), polyamide (MESH:D009757), sodium citrate (MESH:D000077559), epinephrine (MESH:D004837), calcium chloride (MESH:D002122), EDTA (MESH:D004492)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], hepatitis C virus [taxon 11103], Bos taurus (bovine, species) [taxon 9913], Treponema pallidum (species) [taxon 160], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Homo sapiens (human, species) [taxon 9606]

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13009063/full.md

---
Source: https://tomesphere.com/paper/PMC13009063